COMPARISON OF METFORMIN EFFECTIVENESS AMONG OBESE AND NON-OBESE WOMEN DIAGNOSED WITH PCOS (POLYCYSTIC OVARIAN SYNDROME)

Objective: This research aimed to evaluate the effectiveness of metformin for PCOS (Polycystic Ovarian Syndrome) second line monotherapy of the patients. Methodology: This case series was conducted on a total of one hundred patients at Jinnah Hospital, Lahore (February to December 2017). We calculated the research sample with Confidence Interval (95%), expected metformin efficacy (29%) and freedom degree (7%) [6]. We included confirmed PCOS patients with clomiphene citrate treatment and any BMI range. Whereas, we did not include the patients with an intake of other than clomiphene citrate and any other known systemic disease. Physical examination history and second menstrual cycle hormonal profile (serum LH, FSH, testosterone, Prolactin and mid-luteal phase progesterone) along with ultrasound of pelvis were also carried out for every patient. Patients started receiving monotherapy of Metformin through an oral dose of (500 mg) per day for a period of one week and for another week the intake of the dose was (1500 mg) every day for a period of six months by non-obese females. We maintained a dose of (200 mg) among two groups obese female groups. During follow up visits after three weeks the researcher assessed the level of Serum Progesterone. Research documented the ovulation after a period of six months of metformin administration. Metformin was effective in the ovulation was at mid-luteal phase on the 21st day along with an indication of ovulation having progesterone more than (25 ng/ml). We documented every outcome on a designated proforma and statistical analysis with the help of SPSS software. Results: The research was carried out on one hundred patients who were selected in the age bracket of (20 – 40) years with an average age of (29.47 ± 6.23) years. Further distribution of age bracket was such as 57 patients were in the age bracket of (20 – 30) years and 43 patients were in the age bracket of (31 – 40) years. Metformin effectiveness in PCOS was reported in 63 women: whereas, 37 women reported no effect of metformin. Metformin effectiveness in terms of BMI was such that 12 out of 32 patients were obese (37.5%) and 51 out of 68 patients were non-obese (75%). Conclusion: We conclude that PCOS management is effectively possible by metformin; however, higher efficacy is significant in the PCOS non-obese women. Keywords: Metformin, PCOS (Polycystic Ovarian Syndrome), Effectiveness, Obese and Non-Obese